Shares of Zymeworks Inc. ZYME rallied 14% in premarket trading on Thursday after the company and Jazz Pharmaceuticals Inc. JAZZ said their experimental cancer drug had an overall survival rate of 84% in patients being treated for a type of metastatic gastroesophageal adenocarcinoma after 18 months. The companies are testing zanidatamab in combination with chemotherapy as a first-line treatment in an open-label Phase 2 clinical trial.
... Shares of Zymeworks Inc. ZYME rallied 14% in premarket trading on Thursday after the company and Jazz Pharmaceuticals Inc. JAZZ said their experimental cancer drug had an overall survival rate of 84% in patients being treated for a type of metastatic gastroesophageal adenocarcinoma after 18 months. The companies are testing zanidatamab in combination with chemotherapy as a first-line treatment in an open-label Phase 2 clinical trial.